|
Our Subscribers Profit!! EPIC,CYBX,WZE,MIDD,THLD,BRNC Sign Up Now!! Dont Wait!!
(M2 PressWIRE Via Acquire Media NewsEdge) STOCK MARKETING INC PRESENTS :
(NASDAQ: EPIC - Epicor Software Corp.)
(NASDAQ: CYBX - Cyberonics, Inc.)
(NYSE: WZE - Wizzard Software Corp.)
(NASDAQ: MIDD - Middleby Corp. (The))
(NASDAQ: THLD - Threshold Pharmaceuticals, Inc.)
(NASDAQ: BRNC - Bronco Drilling Co., Inc.)
www.StockMarketingInc.com
To sign up for our free Profiles & Alerts :: visit http://www.StockMarketingInc.com
email us!! info@StockMarketingInc.com or call 1-866-583-8960
------------------------------------------------------------------------------------------------------------------------------------------------------------
(NASDAQ: EPIC - Epicor Software Corp.)
LATEST NEWS!!
Epicor(R) to Participate in "ERP Outlook" Panel at the Janney Capital Markets 2009 Software & Services Conference
IRVINE, CA, Nov 06, 2009 -- Epicor Software Corporation (NASDAQ: EPIC), a leading provider of enterprise business software solutions for the midmarket and divisions of the Global 1000, today announced that Epicor Executive Vice President and Chief Financial Officer Michael Pietrini will be participating in the "ERP Outlook" panel at the Janney Capital Markets 2009 Software & Services Conference in New York City on Wednesday, November 11, 2009, at 9:00 a.m. Eastern time.
All of the panels at the Janney Conference are being webcast live and may be accessed at http://cc.talkpoint.com/jann001/111109a_rb/.
About Epicor Software Corporation Epicor Software is a global leader delivering business software solutions to the manufacturing, distribution, retail, hospitality and services industries. With 20,000 customers in over 150 countries, Epicor provides integrated enterprise resource planning (ERP), customer relationship management (CRM), supply chain management (SCM) and enterprise retail software solutions that enable companies to drive increased efficiency and improve profitability. Founded in 1984, Epicor celebrates 25 years of technology innovation delivering business solutions that provide the scalability and flexibility businesses need to build competitive advantage. Epicor provides a comprehensive range of services with a single point of accountability that promotes rapid return on investment and low total cost of ownership, whether operating business on a local, regional or global scale. The Company's worldwide headquarters are located in Irvine, California with offices and affiliates around the world. For more information, visit www.epicor.com.
------------------------------------------------------------------------------------------------------------------------------------------------------------
(NASDAQ: CYBX - Cyberonics, Inc.)
LATEST NEWS!!
Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 Second Quarter Financial Results
HOUSTON, Nov 06, 2009 -- Cyberonics, Inc. (Nasdaq: CYBX) today announced that the company will report financial results for the second quarter ended October 23, 2009 of its fiscal year ending April 30, 2010 on Wednesday, November 18, 2009 at 5:00 PM EST. The company will conduct a conference call to discuss those results on Thursday, November 19, 2009 at 9:00 AM EST.
Fiscal Year 2010 Second Quarter Results Conference Call Instructions To listen to the conference call live by telephone dial 877-313-8035 (if dialing from within the U.S.) or 706-679-4838 (if dialing from outside the U.S.). The conference ID is 40115998. Presentation slides will be available on-line at www.cyberonics.com no later than 8:00 AM EST on Thursday, November 19, 2009. A replay of the conference call will be available approximately two hours after the completion of the conference call by dialing 800-642-1687 (if dialing from within the U.S.) or 706-645-9291 (if dialing from outside the U.S.). The replay conference ID access code is 40115998. The replay will be available for one week on the above number and subsequently on the company's website for a period of six months.
About Cyberonics, Inc. and VNS Therapy(TM) Cyberonics, Inc. (NASDAQ:CYBX) is a medical technology company with core expertise in neuromodulation. The company developed and markets the Vagus Nerve Stimulation (VNS) Therapy(TM) System, which is FDA-approved for the treatments of epilepsy and treatment-resistant depression. The VNS Therapy System uses a surgically implanted medical device that delivers electrical pulsed signals to the vagus nerve. Cyberonics markets the VNS Therapy System in selected markets worldwide.
Additional information on Cyberonics and VNS Therapy is available at www.cyberonics.com
------------------------------------------------------------------------------------------------------------------------------------------------------------
(NYSE: WZE - Wizzard Software Corp.)
LATEST NEWS!!
Wizzard Media Podcasts Score an iPhone App Five Bagger
Five Podcast Apps Hit Their Respective Top 100 Lists
PITTSBURGH, Nov 06, 2009 -- Wizzard Media (NYSE Amex: WZE), the world's leading podcast network, announced today that five of the newly released podcast Apps have landed on the 100 Top Paid Apps list in the iTunes(R) App Store.
The Mac OS Ken App, ranked #31 in the News category of the App store and priced at $2.99, is the companion App for the Mac OS Ken podcast which is currently ranked as the #55 Technology podcast in iTunes.
The Best of the Left App, ranked #48 in the News category of the App store and priced at $1.99, is the companion App for the Best of the Left podcast which is currently ranked as the #32 News & Politics podcast in iTunes.
The Anime Pulse App, ranked #63 in the News category of the App store and priced at $1.99, is the companion App for the Anime Pulse podcast which is currently ranked as the #37 TV & Film audio podcast in iTunes.
The Paranormal Podcast App, ranked #94 in the News category of the App store and priced at $1.99, is the companion App for the Paranormal Podcast which is currently ranked as the #14 Science & Medicine podcast in iTunes.
The Learn Adobe Creative Suite App, ranked #37 in the Education category of the App store and priced at $1.99, is the companion App for the Learn Adobe Creative Suite podcast which is currently ranked as the #28 Technology podcast in iTunes.
Wizzard Media is offering customized podcast Apps for the iPhone to the podcast publishers on the Wizzard Network as well as other top ranked, off-network podcast publishers. This is a new opportunity for them to monetize their show, offering bonus content and new social communication features to their audience. There are currently 70 podcast Apps for sale in the Wizzard Media section of the iTunes App store with 60 more awaiting approval. http://www.itunes.com/wizzardmedia About Wizzard Media: Wizzard Media provides publishing and distribution services to podcasters and monetization services for podcasters. Wizzard Media is the industry's leading podcasting network with an unprecedented 1.2 billion download requests in 2008. Podcasts are a means for independent and professional content creators to publish audio and video shows for the world to enjoy over the Internet or on mp3 players, such as the Apple iPod(R), iPhone(R) and the Microsoft Zune(R). Podcasting is a relatively new phenomenon, but Wizzard Media collectively broadcasts millions of podcast downloads per day through media aggregators like Apple's iTunes and Microsoft's Zune Marketplace. For more information, please visit www.wizzardsoftware.com/media . Wizzard Media is a division of Wizzard Software, a leader in speech technology distribution and development.
------------------------------------------------------------------------------------------------------------------------------------------------------------
(NASDAQ: MIDD - Middleby Corp. (The))
LATEST NEWS!!
The Middleby Corporation Schedules Third Quarter Earnings Release and Conference Call
ELGIN, Ill., Nov 06, 2009 -- The Middleby Corporation (NASDAQ: MIDD) today announced it will release 2009 third quarter earnings on Monday, November 9 after the market closes. The company has scheduled a conference call to discuss the results at 9:30 a.m. Central Time on Tuesday, November 10. The call can be accessed by dialing (212) 659-4245 and providing conference code 528529#. The conference call is accessible through the Investor Relations section of the company website at www.middleby.com.
About The Middleby Corporation The Middleby Corporation is a global leader in the foodservice equipment industry. The company develops, manufactures, markets and services a broad line of equipment used for commercial food cooking, preparation and processing. The company's leading equipment brands serving the commercial foodservice industry include Anets(R), Blodgett(R), Blodgett Combi(R), Blodgett Range(R), Bloomfield(R), Carter Hoffmann(R), CookTek(R), CTX(R), FriFri(R), Giga(R), Holman(R), Houno(R), Jade(R), Lang(R), MagiKitch'n(R), Middleby Marshall(R), Nu-Vu(R), Pitco Frialator(R), Southbend(R), Star(R), Toastmaster(R) Turbochef(R) and Wells(R). The company's leading equipment brands serving the food processing industry include Alkar(R), MP Equipment(R), and RapidPak(R). The Middleby Corporation was recognized by Business Week as one of the Top 100 Hot Growth Companies of 2007 and 2008 and by Forbes as one of the Best Small Companies in 2007, 2008 and 2009.
For further information about Middleby, visit www.middleby.com.
------------------------------------------------------------------------------------------------------------------------------------------------------------
(NASDAQ: THLD - Threshold Pharmaceuticals, Inc.)
LATEST NEWS!!
Threshold Pharmaceuticals Presents Interim Data From a Phase 1/2 Clinical Trial of TH-302 at Sarcoma Meeting
REDWOOD CITY, Calif., Nov 6, 2009 -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 15th Annual Connective Tissue Oncology Society (CTOS) Meeting taking place in Miami Beach, Florida from November 5 to 7, 2009.
Today's presentation focused on a clinical trial, the 403 trial, which is investigating TH-302 in combination with doxorubicin in patients with soft tissue sarcoma who have not received prior doxorubicin. Twelve patients have had at least one evaluable post-treatment tumor assessment, including 3 (25%) with a partial response (PR) as measured by RECIST (Response Evaluation Criteria In Solid Tumors). Two of the PRs are confirmed, including one patient who has remained on study for 33 weeks. One of the PRs was unconfirmed due to progression at the subsequent assessment. Five of the 12 patients continue to receive TH-302 after receiving TH-302 for 3 to 13 three-week cycles. Seven (58%) patients achieved stable disease while 2 (17%) had progressive disease. Additional patients are being enrolled to better define the extent of the tumor response activity.
"For sarcoma patients, median survival is about one year regardless of stage of disease, so we are definitely in need of new agents to help these patients. We believe that TH-302 may 'complement' doxorubicin, the standard of care in sarcoma, and treat that portion of the tumor that typically does not respond to this traditional chemotherapy agent," said John Curd, M.D., Threshold's chief medical officer. "This clinical trial has thus far established that TH-302 can be safely combined with full doses of doxorubicin, and the preliminary data suggests that TH-302 may add to the activity and durability of doxorubicin." TH-302 continues to be tolerated and there have been no new unexpected adverse events in the 14 patients assessed for safety. Nausea was the most commonly reported adverse event and was reported in 8 (57%) patients. After observing significant, but not dose limiting toxicity at a TH-302 dose of 240 mg/m2, prophylactic growth factor support was initiated. Two dose limiting toxicities, grade 3 cellulitis with grade 4 neutropenia and grade 4 thrombocytopenia, were observed in 2 of 4 patients treated at a TH-302 dose of 340 mg/m2. The maximum tolerated dose (MTD) was then established at 300 mg/m2. Skin toxicity is common with 9 of 14 (64%) patients having at least one skin adverse event. All were grade 1 or 2 with the exception of the one patient with grade 3 cellulitis. Eight (57%) patients had a mucosal adverse event; all were grade 1 or 2.
A copy of the poster may be obtained by calling the Company.
Abbout The Clinical Trial The 403 trial is a Phase 1/2, multicenter, dose escalation trial to determine the safety, efficacy and pharmacokinetics of TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. The trial was initiated in September 2008. The trial will enroll up to 36 patients including 12 patients treated at the MTD as part of the dose expansion component of the trial. TH-302 is administered intravenously on days 1 and 8 of a 21 day cycle. Doxorubicin is dosed according to its package insert (75 mg/m2 on day 1 of the 21 day cycle). The Phase 1/2 clinical trial has completed the dose escalation component, reached the MTD and is currently enrolling patients in the dose expansion cohort.
The Company has two additional ongoing clinical trials of TH-302. The Company is in the process of completing a Phase 1/2 clinical trial of TH-302 in combination with various chemotherapies in patients with advanced solid tumors. The Company is also continuing a Phase 1/2 clinical trial of TH-302 as monotherapy in patients with advanced solid tumors.
About Threshold Pharmaceuticals Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit the website (www.thresholdpharm.com).
------------------------------------------------------------------------------------------------------------------------------------------------------------
(NASDAQ: BRNC - Bronco Drilling Co., Inc.)
LATEST NEWS!!
Bronco Drilling Company, Inc. Announces Third Quarter Results
OKLAHOMA CITY, Nov 06, 2009 -- Bronco Drilling Company, Inc., (Nasdaq/GS:BRNC), announced today financial and operational results for the three months and nine months ended September 30, 2009.
Consolidated Results Revenues for the third quarter of 2009 were $16.2 million compared to revenue of $27.5 million for the previous quarter and $73.0 million for the third quarter of 2008. Net loss for the third quarter of 2009 was $42.7 million compared to a net loss of $7.2 million for the previous quarter and a net loss of $0.9 million for the third quarter of 2008. The Company's fully diluted earnings per share for the quarter ended September 30, 2009, were a loss of $1.60 based on 26.7 million shares.
Third quarter results include several non-recurring items. The company wrote down its investment in Challenger Limited by $21.2 million. The company recognized a loss of $24.0 million in conjunction with the company's sale of a 60% ownership interest in Bronco Drilling MX, S. de R.L. de C.V. ("Bronco MX") in the joint venture transaction with Carso Infraestructura y Constuccion, S.A.B. de C.V. The company also recognized expense of $1.3 million related to the drilling rigs contributed to Bronco MX in the joint venture transaction. The retirement of the company's previous credit facility resulted in a loss on early debt extinguishment of $2.9 million. The new credit facility with Banco Inbursa, S.A. and the joint venture transaction, which were both entered into during the quarter, resulted in certain advisory fees of $1.0 million. Additionally, the company recorded a loss of $1.6 million related to the change in fair value of the warrants issued in conjunction with the new credit facility. Excluding all non-recurring items and the loss on the warrants would result in a fully diluted loss per share for the quarter of $0.37.
Land Drilling Average marketed land rigs for the third quarter of 2009 were 45 compared to 45 for the previous quarter and 42 for the third quarter of 2008. Revenue days for the quarter decreased to 980 from 1,311 for the previous quarter and from 3,208 for the third quarter of 2008. Utilization for the third quarter of 2009 was 23% compared to 32% for the previous quarter and 84% for the third quarter of 2008. Excluding non-recurring items, average daily cash margins for our land drilling fleet for the quarter ended September 30, 2009, were $3,576 compared to $6,304 for the previous quarter and $7,582 for the third quarter of 2008.
About Bronco Drilling Bronco Drilling Company, Inc., a publicly held company headquartered in Edmond, Oklahoma, is a provider of contract land drilling services and workover services to oil and natural gas exploration and production companies. Bronco's common stock is quoted on The Nasdaq Global Select Market under the symbol "BRNC." For more information about Bronco Drilling Company, Inc., visit http://www.broncodrill.com.
------------------------------------------------------------------------------------------------------------------------------------------------------------
About StockMarketingInc.com
StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.
((Comments on this story may be sent to info@m2.com))
(c) 2009 M2 COMMUNICATIONS
[ Back To TMCnet.com's Homepage ]
|
INDUSTRIES
Activate Email 
Find Solutions for Enterprises, SMBs & Service Providers at the INTERNET TELEPHONY Conference and EXPO East, January 20-22, 2010. Miami, FL.
